[Plasma, renal and tumor determination of total platinum during predictive tests of chemosensitivity of human tumor implants in the renal capsule in syngeneic mice].
During the study of chemotherapy responsiveness of twenty nine human tumors by 6 day subrenal capsule assay (SRCA), we measured, after cisplatinum regimen, the total platinum in human tumor implants and in mice plasma and renal tissue. The plasmatic (m = 0.36 +/- 0.13 microgram/ml) and renal (m = 16.1 +/- 6.4 ng/ml) total platinum concentrations are correlated. In human tumor implants the total platinum is measurable in only ten cases (above the minimum value of 7 ng/mg). There are no correlation between the tumor total platinum concentrations and the tumor cisplatinum chemosensitivity. The study is an example of anti-cancer drugs dosage in SRCA.
Favre
R
R
Institut J. Paoli-I, Calmettes, Service d'Hématologie et de Chimiothérapie, Marseille, France.
Hecquet
B
B
D000818:Animals; D002945:Cisplatin / Q000493:pharmacokinetics*; D004343:Drug Implants; D006801:Humans; D007668:Kidney / Q000032:analysis*; D051379:Mice; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000032:analysis*; D010984:Platinum / Q000008:administration & dosage / Q000032:analysis* / Q000097:blood; D013370:Subrenal Capsule Assay; D014018:Tissue Distribution; D014185:Transplantation, Isogeneic
D004343:Drug Implants; D010984:Platinum; D002945:Cisplatin
Dosages plasmatiques, rénaux et tumoraux du platine total au cours des de prévision de chimiosensibilité par implants de tumeur humaine sous la capsule rénale de la souris syngénique.